Amyris Builds Post-IPO Momentum

Synthetic biology firm Amyris (Emeryville, CA) continues to accrue an impressive list of partners as it ramps up production of farnesene, a versatile C15 hydrocarbon and the company’s first commercial product. Founded in 2003, Amyris originally set out to develop yeast that would produce a precursor to artemisinin, a potent anti-malaria drug whose production volumes were limited by a long process time. After that project was turned over royalty-free to sanofi-aventis for larger-scale development, Amyris shifted its attention to the other value compounds its...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers